Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Krystal Biotech (KRYS) Total Non-Current Liabilities: 2024-2025

Historic Total Non-Current Liabilities for Krystal Biotech (KRYS) over the last 2 years, with Sep 2025 value amounting to $99.1 million.

  • Krystal Biotech's Total Non-Current Liabilities rose 3.52% to $99.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $99.1 million, marking a year-over-year increase of 3.52%. This contributed to the annual value of $108.0 million for FY2024, which is N/A change from last year.
  • According to the latest figures from Q3 2025, Krystal Biotech's Total Non-Current Liabilities is $99.1 million, which was up 4.35% from $94.9 million recorded in Q2 2025.
  • Over the past 5 years, Krystal Biotech's Total Non-Current Liabilities peaked at $108.0 million during Q4 2024, and registered a low of $78.2 million during Q2 2024.
  • Its 2-year average for Total Non-Current Liabilities is $93.9 million, with a median of $95.3 million in 2024.
  • Data for Krystal Biotech's Total Non-Current Liabilities shows a peak YoY rose of 21.45% (in 2025) over the last 5 years.
  • Krystal Biotech's Total Non-Current Liabilities (Quarterly) stood at $108.0 million in 2024, then grew by 3.52% to $99.1 million in 2025.
  • Its Total Non-Current Liabilities stands at $99.1 million for Q3 2025, versus $94.9 million for Q2 2025 and $87.7 million for Q1 2025.